In re Vioxx Products Liability Litigation

230 F.R.D. 473, 2005 WL 2036797, 2005 U.S. Dist. LEXIS 17806
District Court, E.D. Louisiana·Decided July 22, 2005·No. No. MDL 1657·Published·Cited by 8 cases

Opinion

[474]*474ORDER AND REASONS

FALLON, District Judge.

On June 29, 2005, the Court heard oral argument on Plaintiffs’ Motion to Modify the Court’s June 6, 2005 Order and Reasons. For the following reasons, the Plaintiffs’ motion is GRANTED and the Court’s June 6, 2005 Order and Reasons is modified to apply to the Plaintiffs in circumstances where the prescribing physician has been named as a defendant.

I. Plaintiffs’ Motion to Modify

In an Order issued June 6, 2005, this Court ruled that any attorney or representative of any party wishing to interview a Plaintiffs prescribing physicians must serve Liaison Counsel for the opposing party with five days notice of such interview. According to the Order, opposing counsel would then be permitted to attend and participate in the noticed interview, but if opposing counsel decided not to participate in the interview, the noticing party could conduct said interview without opposing counsel’s presence. The Plaintiffs have moved the Court to modify this Order by limiting the applicability of the Order as it applies to Plaintiffs’ counsel to circumstances in which the treating physician actually has been named as a defendant. Plaintiffs seek this modification for several reasons:

First they argue that the Court’s order is unprecedented and inconsistent with practice in other major venues of the Vioxx litigation. The Plaintiffs point to other MDLs as well as Vioxx litigation in various states in which courts have allowed Plaintiffs’ counsel to contact treating physicians without the presence of defense counsel.

Second, Plaintiffs suggest that the Court’s decision has discouraged participation in the MDL.

Third, Plaintiffs argue that the Court’s concern about Plaintiffs’ contact with physicians who are potential defendants is not needed because there is no evidence of impropriety on the part of Plaintiffs’ counsel with regard to communications with physicians. The Plaintiffs further state that amendments to add physicians are unlikely because the Plaintiffs’ main theory is that doctors were never allowed to become learned intermediaries since Merck failed to disclose known risks of heart attacks to the medical community. Therefore, adding doctors as defendants in most circumstances would undermine this theory by suggesting that the doctors are at fault. Accordingly, the Plaintiffs believe that the Court’s June 6, 2005 Order should be modified to conform with the Court’s policy reasons for denying the ex parte communications for any party, and only should apply to the Plaintiffs where the treating physician has an interest in the litigation because he or she has been named as a defendant.

Merck opposes such modification, claiming that the Plaintiffs have used the motion for reconsideration to rehash previous arguments. Merck argues that the Court’s concerns regarding Plaintiffs’ communications with doctors is not unfounded. To support this position, Merck points to a letter in which a plaintiffs’ lawyer threatened to name doctors as defendants in Vioxx suits and to tell the doctors that it was Merck’s fault because Merck refused to waive its right to remove Vioxx cases to federal court. Further, Merck points to a plaintiffs’ attorney working for a firm represented on the PSC who, at a Vioxx conference, encouraged other plaintiffs’ lawyers to sway physicians to accept plaintiffs’ theories in Vioxx cases. Merck questions why Plaintiffs cannot obtain factual information from doctors in the presence of a defense attorney. According to Merck, the real concern regarding undue influence is with physicians who have not already been sued, because those who have been sued will be represented by counsel. Further, Merck argues that the Court should not skew the law in order to encourage more federal court filings, as Merck believes the Plaintiffs are advocating.

After considering the briefs and arguments of counsel the Court revisits its prior ruling and tests its theoretical basis, its basis in logic, and its practical effect.

II. Analysis

A motion to reconsider should be granted only where the movant demonstrates: (1) intervening change in controlling law, (2) the availability of new evidence not [475]*475previously available, or (3) the need to correct a clear error of law or to prevent injustice.1 “Reconsideration of an order is an extraordinary remedy which courts should use sparingly.”2 Further, motions for reconsideration are not to be used “to re-debate the merits of a particular motion.”3

In the instant case, the Plaintiffs have not satisfied requisites (1) or (2) of the standard for motions to reconsider. However, the Plaintiffs have claimed that the Court’s order should be modified to prevent injustice. Therefore, the Plaintiffs have filed a valid motion for reconsideration. In fact, the Plaintiffs have characterized their motion as a motion to modify rather than a motion for reconsideration because the Plaintiffs have not taken issue with the Court’s reasoning. Rather, the Plaintiffs argue that the Court’s reasoning need not lead to such a broad prohibition against Plaintiffs’ contacts with their own prescribing physicians.

At the outset, the Court’s notes that the purpose of the June 6, 2005 opinion and order was to put Plaintiffs and Defendants on an equal footing with respect to interviewing the prescribing physicians. While the logic and reasoning of the opinion are sound, the practical effect has created unintended consequences that can cause more problems than it sought to solve. This is of concern and causes the Court to reevaluate its prior approach.

It is important to recognize that the current issue is a discovery issue and not a substantive one. Discovery is intended to assist counsel for all parties to prepare for trial. It is not intended to make life more difficult or to distract them from the primary issues of the litigation. If or when it does, the discovery method needs to be reevaluated. This observation is not intended to trivialize discovery; it is an essential part of a case, but it has to be kept in perspective.

With this principle in mind, the Court turns to the issues raised by the Plaintiffs. Plaintiffs point out that in determining whether to take or keep a case, it is often important for a plaintiffs counsel to interview the plaintiffs treating physician regarding the plaintiffs personal medical history. The approach taken in the Court’s previous Order presents an obstacle to this important process. Furthermore, the Court’s initial approach has had a chilling effect on the MDL process, which was designed to coordinate litigation in one forum. While an adverse effect on the MDL process should not be determinative in the Court’s decision on how to handle communications with physicians, it is not an irrelevant issue for MDL transferee judges. The Court’s original approach has also interfered with the objective of the MDL process by placing Plaintiffs’ counsel in a potential malpractice conundrum. Plaintiffs’ counsel has to choose between filing their clients’ cases in this MDL where they could not engage in private discussions with the plaintifPs treating physician, filing their cases in state courts that would allow them to have ex parte communications with the physicians, or first filing in state court in order to interview doctors and then removing to federal court and becoming part of the MDL.

Free access — add to your briefcase to read the full text and ask questions with AI

In re Vioxx Products Liability Litigation, 230 F.R.D. 473, 2005 WL 2036797, 2005 U.S. Dist. LEXIS 17806 (E.D. La. 2005).

230 F.R.D. 473 (In re Vioxx Products Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related